(Q34696326)

4 August 2017

1 reference

title

New treatments for Hodgkin's disease (English)

1 reference

4 August 2017

Jan-Peter Glossmann

1

1 reference

4 August 2017

Andreas Josting

series ordinal

2

1 reference

4 August 2017

Volker Diehl

series ordinal

3

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Current Treatment Options in Oncology

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

283-290

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-002-0028-x

4 August 2017

exact match

0 references

cites work

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-002-0028-X

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease

21 January 2018

1 reference

12 December 2020

Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.

1 reference

12 December 2020

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

12 December 2020

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

12 December 2020

Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone

1 reference

12 December 2020

Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy

1 reference

12 December 2020

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

1 reference

12 December 2020

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

1 reference

12 December 2020

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

12 December 2020

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

12 December 2020

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

12 December 2020

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

12 December 2020

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

12 December 2020

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

1 reference

12 December 2020

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

12 December 2020

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

12 December 2020

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

12 December 2020

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of

1 reference

12 December 2020

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

12 December 2020

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

12 December 2020

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors

1 reference

12 December 2020

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

1 reference

12 December 2020

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

12 December 2020

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

1 reference

12 December 2020

Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives

1 reference

12 December 2020

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group

1 reference

12 December 2020

Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

1 reference

12 December 2020

Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study

1 reference

12 December 2020

10.1007/S11864-002-0028-X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1016213248

0 references

1 reference